3 ms·
It is exciting. But what's a bit unclear (to me) is how re-usable safety testing is. Are we going to arrive at stage where we can "push to production" after thi
by iguy 6y ago
It is exciting. But what's a bit unclear (to me) is how re-usable safety testing is. Are we going to arrive at stage where we can "push to production" after this 48 hour design phase, or are we going to need months-to-years of trials for each new code?
- xiphias2 6y agoThere's a huge difference between months and years. The delivery platform is reusable, which is a big difference from older vaccines, where the virus that is delivered can be used only once (Sputnik-V vaccine uses 2 different delivery platforms _because of_ this. The other thing to look at is efficiency: as the vaccines can deliver mRNAs that cells express anyways in healthy people, the lesser toxicity can mean a higher likelihood of success for the drug (which is the main problem with drug development in the last 10-20 years).